Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy

Pharmaceutics. 2021 Jul 22;13(8):1120. doi: 10.3390/pharmaceutics13081120.

Abstract

Cancer stem cells (CSCs) are reportedly responsible for the initiation and propagation of cancer. Since CSCs are highly resistant to conventional chemo- and radiotherapy, they are considered the main cause of cancer relapse and metastasis. Salinomycin (Sali), an anticoccidial polyether antibiotic, has emerged as a promising new candidate for cancer therapy, with selective cytotoxicity against CSCs in various malignancies. Nanotechnology provides an efficient means of delivering Sali to tumors in view of reducing collateral damage to healthy tissues and enhancing the therapeutic outcome. This review offers an insight into the most recent advances in cancer therapy using Sali-based nanocarriers.

Keywords: cancer; cancer stem cells; drug delivery system; nanoparticles; nanosystems; nanotechnology; salinomycin.

Publication types

  • Review